Penserra Capital Management LLC Sells 91,424 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Penserra Capital Management LLC lessened its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 19.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 383,836 shares of the company's stock after selling 91,424 shares during the quarter. Penserra Capital Management LLC owned approximately 0.18% of Hims & Hers Health worth $7,069,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Robeco Institutional Asset Management B.V. purchased a new stake in Hims & Hers Health in the 3rd quarter worth approximately $604,000. Carnegie Investment Counsel purchased a new stake in Hims & Hers Health in the 3rd quarter worth approximately $5,531,000. Royce & Associates LP lifted its position in Hims & Hers Health by 17.0% in the 3rd quarter. Royce & Associates LP now owns 341,000 shares of the company's stock worth $6,281,000 after buying an additional 49,500 shares in the last quarter. Versor Investments LP purchased a new stake in Hims & Hers Health in the 3rd quarter worth approximately $634,000. Finally, International Assets Investment Management LLC bought a new position in shares of Hims & Hers Health during the 3rd quarter valued at $6,790,000. Hedge funds and other institutional investors own 63.52% of the company's stock.

Insider Buying and Selling

In other Hims & Hers Health news, COO Melissa Baird sold 58,750 shares of Hims & Hers Health stock in a transaction on Monday, November 18th. The shares were sold at an average price of $21.04, for a total value of $1,236,100.00. Following the sale, the chief operating officer now directly owns 630,166 shares in the company, valued at approximately $13,258,692.64. The trade was a 8.53 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Soleil Boughton sold 2,339 shares of Hims & Hers Health stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $16.50, for a total transaction of $38,593.50. Following the completion of the sale, the insider now owns 176,952 shares in the company, valued at $2,919,708. The trade was a 1.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,056,183 shares of company stock worth $21,501,682 over the last ninety days. Company insiders own 17.71% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft raised their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a "hold" rating in a report on Wednesday, November 6th. TD Cowen reiterated a "buy" rating and issued a $28.00 target price on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Piper Sandler reiterated a "neutral" rating and issued a $21.00 target price (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Imperial Capital lowered shares of Hims & Hers Health from an "outperform" rating to an "in-line" rating in a research note on Friday, August 9th. Finally, Needham & Company LLC assumed coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They issued a "buy" rating and a $24.00 target price on the stock. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $20.71.

Hims & Hers Health Stock Up 23.9 %

HIMS stock traded up $6.06 during midday trading on Monday, reaching $31.39. The company's stock had a trading volume of 49,364,490 shares, compared to its average volume of 9,698,104. Hims & Hers Health, Inc. has a 52 week low of $8.09 and a 52 week high of $31.40. The stock has a market cap of $6.86 billion, a PE ratio of 71.34 and a beta of 1.06. The business's 50-day simple moving average is $20.85 and its 200-day simple moving average is $19.44.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million for the quarter, compared to analysts' expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business's quarterly revenue was up 77.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.04) earnings per share. As a group, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.